Assessment of Rare Cancers and Sarcoma Policy and Sarcoma Drug Approvals in Latin America: A Report From the LACOG Sarcoma Group

Dias E Silva D.; Lopes David B.B.; Pires De Camargo V.; Zon Filipi R.; González Donna M.L.; Haro Varas J.C.; Ramella Munhoz R.; Zapata M.L.; Cunha Martins C.L.; Chacon M.; Schmerling R.; Jesus Garcia R.; Carmagnani Pestana R. · JCO Global Oncology (2025) · DOI: 10.1200/go.24.00239

Resumen

PURPOSE The availability of drugs and national public policies for patients with rare cancers, including sarcomas, varies in different parts of the world. METHODS In this manuscript, we have conducted a comprehensive analysis to evaluate rare cancer policies in Latin American countries' national policy documents. Additionally, we have reviewed the approvals for sarcoma drugs in selected Latin American countries and compared them with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals. RESULTS The documents reviewed showed a lack of explicit focus on rare cancers, with no mention in 70% of the countries analyzed. Drug approval data reveal that in the last 15 years, the FDA and EMA have approved 19 and 13 drugs for sarcoma, whereas their Latin American counterparts, namely ANVISA, ANMAT, and COFEPRIS, approved six, eight, and seven drugs, respectively. CONCLUSION Our data suggest that improving rare cancer and sarcoma care in Latin America requires enhanced collaboration for better rare cancer policies. © American Society of Clinical Oncology.